Fullhope Biomedical Co

Fullhope Biomedical Co EBITDA per Share

The EBITDA per Share of Fullhope Biomedical Co (7773.TWO) as of Oct 25, 2026 is -1.61 TWD. In the previous year, EBITDA per Share was -1.10 TWD — a change of 46.75% (lower).

EBITDA per Share

-1.61TWD

YoY

46.75%

Last updated:

EBITDA per Share of Fullhope Biomedical Co is 2024 -1.61 TWD. EBITDA per Share of Fullhope Biomedical Co was 2023 -1.10 TWD. It decreases by 46.75% lower compared to the previous year.

The Fullhope Biomedical Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2022
-1.11 TWD
Jan 1, 2023
-1.10 TWD
Jan 1, 2024
-1.61 TWD
The Fullhope Biomedical Co EBITDA per Share history
YEAREBITDA per ShareYoY
-1.61TWD+46.75%
-1.10TWD-0.58%
-1.11TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Fullhope Biomedical Co Stock analysis

What does Fullhope Biomedical Co do? Fullhope Biomedical Co Ltd generates revenue through precision diagnosis and regenerative medicine products. The company offers immune function analysis and circulating tumor cell analysis platforms for follow-up disease treatment strategies. In regenerative medicine, Fullhope operates a Good Tissue Practice (GTP) laboratory with a complete immune cell and stem cell manufacturing platform producing cell products. The company targets medical institutions and healthcare providers seeking advanced diagnostic and regenerative solutions. Fullhope Biomedical Co Ltd focuses on developing immune function analysis and circulating tumor cell analysis platforms within precision diagnosis. The regenerative medicine segment includes GTP-compliant laboratory services and cell product manufacturing. Medical institutions and healthcare providers are the primary customers purchasing these specialized diagnostic and regenerative medicine solutions. The company's revenue streams come from both precision diagnosis platforms and regenerative medicine services. Immune function analysis and circulating tumor cell analysis platforms provide comprehensive immune system and tumor cell data for treatment planning. GTP laboratory services and cell product manufacturing under regenerative medicine deliver specialized medical solutions to healthcare providers. Fullhope Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Fullhope Biomedical Co stock

EBITDA per Share of Fullhope Biomedical Co is -1.61 TWD in 2024.

EBITDA per Share of Fullhope Biomedical Co changed from -1.10 TWD to -1.61 TWD, representing a 46.75% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Fullhope Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Fullhope Biomedical Co

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Fullhope Biomedical Co